论文部分内容阅读
目的观察唑来膦酸、沙利度胺联合地塞米松治疗多发性骨髓瘤(MM)的疗效及安全性。方法 19例MM患者接受唑来膦酸、沙利度胺联合地塞米松治疗。结果总有效率89.5%。进步者中位生存时间17个月。部分缓解者中位生存时间36个月。骨痛缓解总有效率100%。不良反应轻微,均可耐受。结论唑来膦酸、沙利度胺联合地塞米松治疗MM疗效明显,可延长患者生存期,改善生活质量,不良反应轻,耐受性好。
Objective To observe the efficacy and safety of zoledronic acid, thalidomide combined with dexamethasone in the treatment of multiple myeloma (MM). Methods Nineteen MM patients received zoledronic acid and thalidomide combined with dexamethasone. The total effective rate of 89.5%. Progressive median survival time of 17 months. The median survival time of partial remission was 36 months. The total effective rate of bone pain relief 100%. Minor adverse reactions, can be tolerated. Conclusion Zoledronic acid and thalidomide combined with dexamethasone treatment of MM significant effect, can extend the survival of patients and improve quality of life, adverse reactions, good tolerance.